Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets

• Mayank Dalakoti,
• Salim Virani

Affiliations

Mayank Dalakoti

Department of Cardiology, National University Heart Centre, Singapore; Department of Medicine, Ng Teng Fong General Hospital, Singapore; Department of Public Health and Primary Care, University of Cambridge, United Kingdom; Corresponding author.

Salim Virani

Department of Medicine, The Aga Khan University, Karachi, Pakistan; The Texas Heart Institute, Houston, TX, USA; Section of Cardiovascular Research, Baylor College of Medicine, USA